GlassScriptPhysician profile
Myet Mon Zin
NPI 1912439563
$2,899.91
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $698 · 2023: $2,171 · 2024: $31.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,202.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $640.55 | 2022-2023 | Mounjaro, Jardiance, Trulicity |
| Sanofi-Aventis U.S. LLC | $221.97 | 2022-2024 | |
| Radius Health, INC. | $204.87 | 2022-2023 | |
| Novo Nordisk INC | $185.87 | 2022-2023 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $172.07 | 2022-2024 | Repatha, Evenity, Prolia |
| Mannkind Corporation | $157.00 | 2022-2023 | Afrezza |
| Dexcom, INC. | $151.66 | 2022-2023 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $139.70 | 2023 | Nocdurna, Tlando, Xyosted |
| Organogenesis INC. | $120.44 | 2023 | Puraply |
| Recordati_rare_diseases_inc. | $102.89 | 2022-2023 | Signifor Lar, Isturisa |
| Tandem Diabetes Care, INC. | $98.38 | 2022-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.56 | 2022-2023 | Synjardy, Jardiance |
| Ultragenyx Pharmaceutical INC. | $75.76 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $64.56 | 2022-2023 | Strensiq |
| Horizon Therapeutics Plc | $64.09 | 2023 | Tepezza |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amryt Pharma Holdings LTD | $55.53 | 2023 | Mycapssa |
| Abbvie INC. | $55.47 | 2022-2023 | Synthroid |
| Halozyme INC | $54.77 | 2023 | |
| Xeris Pharmaceuticals, INC. | $34.80 | 2023 | Gvoke Hypopen |
| Nevro Corp. | $33.95 | 2023 | Senza |
| Medtronic, INC. | $27.52 | 2023 | Minimed 780g |
| Ascendis Pharma Endocrinology INC | $25.88 | 2023 | |
| Ibsa Pharma INC. | $24.01 | 2023 | Tirosint, Licart |
| Beta Bionics, INC. | $22.69 | 2023 | Ilet Bionic Pancreas |
| Kyowa Kirin, INC. | $19.92 | 2023 | Crysvita |
| Esperion Therapeutics, INC. | $18.03 | 2023 | Nexletol |
| Cequr Corporation | $17.72 | 2023 | Cequr Simplicity |
| Astrazeneca Pharmaceuticals LP | $17.25 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Myet Mon Zin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.